Clinical outcomes and immunological features of COVID-19 patients receiving B-cell depletion therapy during the Omicron era-Reference-Cited by-同舟云学术

Clinical outcomes and immunological features of COVID-19 patients receiving B-cell depletion therapy during the Omicron era

Published:2023-11-02 Issue:2 Volume:56 Page:116-127
ISSN:2374-4235
Container-title:Infectious Diseases
language:en
Short-container-title:Infectious Diseases

Author:

Lee Chan Mi¹,Kim Minji²³⁴,Park Seong-wook⁵,Kang Chang Kyung¹,Choe Pyoeng Gyun¹,Kim Nam Joong¹,Jo Hyeon Jae¹,Shin Hyun Mu²⁴⁶,Lee Chang-Han²⁴⁵⁶⁷,Kim Hang-Rae²³⁴⁶⁸,Park Wan Beom¹,Oh Myoung-don¹

Affiliation:

1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

2. Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea

3. Department of Anatomy & Cell Biology and Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea

4. BK21 FOUR Biomedical Science Project, Seoul National University College of Medicine, Seoul, Republic of Korea

5. Department of Pharmacology, Seoul National University College of Medicine, Seoul, Republic of Korea

6. Wide River Institute of Immunology, Seoul National University, Hongcheon, Republic of Korea

7. Cancer Research Institute, Seoul National University, Seoul, Republic of Korea

8. Medical Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

Funder

Seoul National University Hospital

SNUH Research Fund

the Bio and Medical Technology Development Program of the National Research Foundation (NRF), the Korean government

the Creative-Pioneering Researchers Program through Seoul National University

the Ministry of Trade, Industry and Energy (MOTIE), and the Korea Institute for Advancement of Technology

Neutralizing Antibody Development Support Centre

Publisher

Informa UK Limited

Subject

Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/23744235.2023.2276784

Reference35 articles.

1. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

2. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders

3. Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution

4. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia

5. Prolonged Coronavirus Disease 2019 in a Patient With Rheumatoid Arthritis on Rituximab Therapy